Navigation Links
MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
Date:6/23/2011

ROCKVILLE, Md., June 23, 2011  /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protege, the Company's Phase 3 clinical study of teplizumab in type 1 diabetes patients, will be presented at the American Diabetes Association's 71st Scientific Sessions symposium in San Diego, California on June 28, 2011 at 9:10 a.m. PDT.

Dr. Nicole Sherry, Director of the Diabetes Center at Massachusetts General Hospital for Children, and a lead investigator in the Protege study, will be presenting the results of the Phase 3 data as well as the results of exploratory post-hoc analyses.

About Teplizumab

Teplizumab, also called MGA031 and hOKT3gamma1 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhance beneficial regulatory T cell functions, thus promoting immune tolerance.  MacroGenics retains full worldwide rights to teplizumab.

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a method for generating cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) technology, which allows the company to incorporate multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.  


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
2. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
5. Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility
6. Lupin Announces Launch of Generic Levaquin® Tablets
7. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
8. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
9. Oxford BioMedica Announces Ocular Programme Update
10. China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health
11. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ZIONA SCIENCE PARK , Israel ... company Kadimastem (TASE: KDST) announced today the signing of a memorandum ... between the companies. The synergy between the companies will assist in ... as a worldwide leader in innovative treatment for severe diseases in ... ...
(Date:12/7/2016)... 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... focused on delivering scientific and medical breakthroughs using ... and Chief Executive Officer Keith Murphy ... December 14, 2016 at 1:00 p.m. Eastern Time ... yet familiar with the Company, an informational video ...
(Date:12/7/2016)... The global  blood screening ... USD 3.9 billion by 2024, based on a ... growth of the market is attributed to the ... by the market players. Demand for blood screening ... rising awareness about transfusion-transmitted diseases, and technological developments ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back ... not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... the children of the world. , In exchange for generous donations, customers will receive ...
(Date:12/7/2016)... ... 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... Voice of America, declared on her radio program in November 2016 the need to ... these bullies attack leaders in corporate America, they are trying to take advantage of ...
(Date:12/7/2016)... Phoenix, Arizona (PRWEB) , ... December 07, 2016 , ... ... Juvederm®, Just in Time For The Holiday Party Season. Save Up To 33% Off ... and Laser Salon is providing the Phoenix Valley with Delightful Deals on ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers ... Plus substantially enhances the WellnessPro platform by expanding the treatment modalities available ...
Breaking Medicine News(10 mins):